Using a connected scale to monitor weight and vitals during lymphoma and myeloma treatment
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
This project will test whether daily use of a connected scale to track weight and heart rate at home can help people with lymphoma or multiple myeloma who are receiving chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Paris) |
| Trial ID | NCT06133426 on ClinicalTrials.gov |
What this trial studies
Thirty adult patients with aggressive non-Hodgkin lymphoma or multiple myeloma receiving systemic chemotherapy (or within the first two cycles or undergoing therapeutic intensification/autograft) will use a Withings Body Comp Pro connected scale for about seven weeks. Participants will be asked to weigh themselves once daily at a consistent time, with weight and available vital data transmitted to a remote monitoring platform accessible to the clinical team. The platform will generate alerts for abnormal changes in predefined clinical parameters to prompt earlier clinical intervention. At study end, investigators will review how patients experienced the tool and analyze the healthcare actions triggered by the alerts.
Who should consider this trial
Good fit: Adults (18+) with aggressive non-Hodgkin lymphoma or multiple myeloma who are starting or within two cycles of systemic chemotherapy or require intensification/autograft, can use the device, speak French, be contacted by phone, return home after initial hospitalization, and provide informed consent are ideal candidates.
Not a fit: Patients with estimated life expectancy under three months, moderate to severe cognitive impairment, inability to use the device, a pacemaker, pregnancy, or currently enrolled in another interventional research project are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could enable earlier detection of clinical deterioration and faster medical response, potentially reducing complications and urgent care needs.
How similar studies have performed: Remote monitoring interventions in oncology and chronic disease have shown promise for early detection of deterioration, but use of a connected scale specifically in hematology patients is relatively novel and not widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 and over (male or female) * Patient suffering from aggressive non-Hodgkin's lymphoma or multiple myeloma with a plan for systemic chemotherapy or having started two cycles or less or patient with the need for therapeutic intensification under the cover of autograft in the context of myeloma or lymphoma * Patient who can be contacted by telephone during their participation in the research * Patient able to return home at the end of their initial hospitalization * Patient affiliated to social security * Patient able to read and speak French * Patient having signed free, informed and written consent Exclusion Criteria: * Patient with an estimated life expectancy \< 3 months * Patient with moderate to severe cognitive impairment (assessed by MMSE \< 20) * Patient with a psychiatric or physical disability that does not allow the use of the device * Patient with a pacemaker * Patient participating in another intervention research project * Pregnant patient * Patient deprived of liberty * Patient under legal protection (guardianship or curatorship)
Where this trial is running
Paris
- Cochin Hospital — Paris, France (Recruiting)
Study contacts
- Study coordinator: Rudy BIRSEN, Dr
- Email: rudy.birsen@aphp.fr
- Phone: 01.58.41.42.90
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.